| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM199511233332107 |
| P698 | PubMed publication ID | 7477122 |
| P2093 | author name string | Woolf SH | |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1401-1405 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Screening for prostate cancer with prostate-specific antigen. An examination of the evidence | |
| P478 | volume | 333 |
| Q52924371 | "Screening" for prostate cancer in New York's skid row: history and implications. |
| Q89834470 | A Comprehensive Analysis of FUT8 Overexpressing Prostate Cancer Cells Reveals the Role of EGFR in Castration Resistance |
| Q46872796 | A guinea pig's view on prostate cancer screening trials |
| Q35729693 | Acute onset-low back pain and hip pain secondary to metastatic prostate cancer: a case report |
| Q39568664 | Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer |
| Q35019287 | Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. |
| Q33480997 | Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood |
| Q35688261 | Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey |
| Q39428483 | Can screening for early-stage prostate cancer be rationalized? |
| Q50882861 | Cancer mortality in Europe: effects of age, cohort of birth and period of death. |
| Q41313350 | Cancer screening in the older patient. |
| Q41577002 | Common urologic disorders. When to treat and when to refer |
| Q60156381 | Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma |
| Q39669391 | Cultural sensitivity and informed decision making about prostate cancer screening |
| Q33979664 | Current challenges in cancer screening. Part II. Prostate cancer screening |
| Q56755305 | Der Umgang mit Wahrscheinlichkeiten und das Vertrauen in die Medizin |
| Q33326514 | Detection of early prostate cancer using a hepsin-targeted imaging agent |
| Q35720563 | Diagnosis and treatment of prostate cancer |
| Q34569429 | Diagnosis of roentgenographically occult lung cancer by sputum cytology |
| Q33543410 | Differentiating prostate disorders |
| Q80396215 | Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites |
| Q39843486 | Does educational printed material manage to change compliance with prostate cancer screening? |
| Q88811002 | Does the prostate volume always effect cancer detection rate in prostate biopsy? Additional role of prostate-specific antigen levels: A retrospective analysis of 2079 patients |
| Q40158040 | Dominance of the alpha1B-adrenergic receptor and its subcellular localization in human and TRAMP prostate cancer cell lines |
| Q31712792 | Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. |
| Q44491148 | Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation |
| Q42558926 | Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer |
| Q36075932 | Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. |
| Q47984250 | FGFR3 mutations in prostate cancer: association with low-grade tumors |
| Q80972908 | Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey |
| Q48788131 | Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer |
| Q33964990 | Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. |
| Q47801824 | High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia |
| Q53069548 | How did the PSA system arise? |
| Q34152258 | Identification of an antibody fragment specific for androgen-dependent prostate cancer cells |
| Q39912228 | Image-based clinical decision support for transrectal ultrasound in the diagnosis of prostate cancer: comparison of multiple logistic regression, artificial neural network, and support vector machine |
| Q73330598 | Informed Consent for Cancer Screening With Prostate-Specific Antigen: How Well Are Men Getting the Message? |
| Q39875520 | Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry |
| Q41474114 | Is screening for prostate cancer the current gold standard?--"yes". |
| Q36217132 | Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? |
| Q37222117 | Latest tests for prostatic neoplasia |
| Q41109717 | Long-term management of the liver transplant recipient |
| Q59706204 | Lowering PSA cutoffs to enhance detection of curable prostate cancer |
| Q41721384 | MR imaging of the prostate and bladder |
| Q74655633 | Male genital cancers |
| Q56894250 | Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer |
| Q81379607 | Metastatic prostate cancer with a normal prostate-specific antigen level |
| Q51935531 | Neuro-fuzzy system for prostate cancer diagnosis. |
| Q41460411 | New approaches to the integrated management of early lung cancer |
| Q40256852 | Notch signalling and voltage-gated Na+ channel activity in human prostate cancer cells: independent modulation of in vitro motility. |
| Q78108870 | Numerical chromosomal anomalies in latent adenocarcinomas of the prostate |
| Q35783202 | Optimization of PSA screening policies: a comparison of the patient and societal perspectives |
| Q77949159 | PSA screening--current controversy |
| Q43013882 | PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group. |
| Q24814107 | PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK |
| Q36325601 | PSA testing: an evolving relationship with prostate cancer screening |
| Q82987640 | PSA velocity and PSA slope |
| Q74325636 | PSA-use in a Spanish industrial area |
| Q40266746 | Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey |
| Q34741600 | Physician perspectives on the importance of facts men ought to know about prostate-specific antigen testing |
| Q36844437 | Physician-patient discussions of controversial cancer screening tests |
| Q34426362 | Posttransplantation care: role of the primary care physician versus transplant center |
| Q39545483 | Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network |
| Q34712987 | Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. |
| Q41377536 | Preventive medicine and screening in older adults |
| Q39438028 | Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen |
| Q73258126 | Prostate cancer |
| Q41500435 | Prostate cancer diagnosis and management |
| Q45112761 | Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results |
| Q34029605 | Prostate cancer: 1. The descriptive epidemiology in Canada |
| Q52898226 | Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. |
| Q39556191 | Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City |
| Q46425753 | Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer |
| Q34030385 | Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer |
| Q59160601 | Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer |
| Q35129362 | Quality of Life and Economic Considerations in the Management of Prostate Cancer |
| Q46675683 | Racial differences in prostate carcinogenesis. Histologic and clinical observations |
| Q57540465 | Reference ranges for serum prostate-specific antigen in black and white men without cancer |
| Q41756875 | Screening and chemoprevention |
| Q34707842 | Screening for prostate cancer in African Americans |
| Q43155149 | Screening without evidence of efficacy |
| Q42766017 | Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial |
| Q73707851 | Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing |
| Q35924328 | Specific aspects of erectile function in urology/andrology |
| Q73641914 | Sputum screening by quantitative microscopy: a new dawn for detection of lung cancer? |
| Q74176749 | Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis |
| Q39687916 | Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. |
| Q33288928 | The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study |
| Q43606006 | The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology |
| Q34193795 | The effect of disease prevention and health promotion on workplace productivity: a literature review |
| Q33843865 | Treatment decisions for localized prostate cancer: asking men what's important |
| Q51739513 | Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution. |
| Q42725643 | Variation in KLK genes, prostate-specific antigen and risk of prostate cancer |
| Q40852795 | Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line |
| Q78860478 | What patients should be told before agreeing to a blood test that could change their lives |
| Q39479473 | What should men know about prostate-specific antigen screening before giving informed consent? |
| Q56775830 | What's wrong with chemoprevention of prostate cancer? |
| Q77527992 | [Analysis of the use of prostate specific antigen (PSA) in a health area of the Community of Madrid] |
Search more.